• 제목/요약/키워드: Anticoagulation drug

검색결과 20건 처리시간 0.019초

항응고제 투여중인 다발성 전신질환자에서 과도한 발치창 출혈부의 진정요법과 국소마취 시행하에 창상주위 봉합과 배농술 통한 출혈과 감염조절 (Bleeding & Infection Control by the Circumferential Suture & Drainage on Active Bleeding Extraction Socket under Sedation And Local Anesthesia in a Multiple Medically Compromised Patient with Anticoagulation Drug)

  • 유재하;김종배
    • 대한치과마취과학회지
    • /
    • 제11권2호
    • /
    • pp.177-182
    • /
    • 2011
  • There are five principal causes for excessive bleeding in the immediate postextraction phase ; (1) Vascular wall alteration (wound infection, scurvy, chemicals, allergy) (2) Disorders of platelet function (genetic defect, drug-aspirin, autoimmune disease) (3) Thrombocytopenic purpuras (radiation, leukemia), (4) Inherited disorders of coagulation (hemophilia, Christmas disease, vitamin deficiency, anticoagulation drug-heparin, coumarin, aspirin, plavix). If the hemorrhage from postextraction wound is unusually aggressive, and then dehydration and airway problem are occurred, the socket must be packed with gelatine sponge(Gelfoam) that was moistened with thrombin and wound closure & pressure dressing are applied. The thrombin clots fibrinogen to produce rapid hemostasis. Gelatine sponges moistened with thrombin provide effective coagulation of hemorrhage from small veins and capillaries. But, in dental alveoli, gelatine sponges may absorb oral microorganisms and cause alveolar osteitis (infection). This is a case report of bleeding and infection control by the circumferential suture and iodoform gauze drainage on infected active bleeding extraction socket under sedation and local anesthesia in a 71-years-old male patient with anticoagulation drug.

항응고제 투여중인 다발성 장애환자에서 골수이식전 발치창 출혈부의 전색과 배농술을 통한 출혈과 감염의 조절 : 증례보고 (BLEEDING & INFECTION CONTROL BY THE PACKING AND DRAINAGE ON BLEEDING EXTRACTION SOCKET BEFORE BONE MARROW TRANSPLANTATION IN A MULTIPLE DISABLED PATIENT WITH ANTICOAGULATION DRUG : REPORT OF A CASE)

  • 유재하;손정석;김종배
    • 대한장애인치과학회지
    • /
    • 제8권1호
    • /
    • pp.15-21
    • /
    • 2012
  • Extraction of all nonrestorable teeth prior to bone marrow transplantation is the major dental management of the patient being prepared for the transplantation. But, there are four principal causes for excessive bleeding in the immediate postextraction phase ; (1) Vascular wall alteration (wound infection, scurvy, chemicals, allergy) (2) Disorders of platelet function (3) Thrombocytopenic purpuras (4) Disorders of coagulation (liver disease, anticoagulation drug-heparin, coumarin, aspirin, plavix) If the hemorrhage from postextraction wound is unusually aggressive, the socket must be packed with local hemostatic agent and wound closure & pressure dressing are applied. But, in dental alveoli, local hemostatic agent (gelfoam, surgcel etc) may absorb oral microorganisms and cause alveolar osteitis (infection). This is a case report of bleeding and infection control by suture, pressure packing and iodoform gauze drainage on infected active bleeding extraction socket under sedation and local anesthesia in a 57-years-old multiple disabled patient with anticoagulation drug.

암환자의 정맥혈전색전증 치료를 위한 새로운 경구용 항응고제 (Novel Oral Anticoagulants for the Treatment of Venous Thromboembolism in Cancer Patients)

  • 김주희;곽혜선
    • 한국임상약학회지
    • /
    • 제26권4호
    • /
    • pp.269-282
    • /
    • 2016
  • Venous thromboembolism, encompassing deep vein thrombosis and pulmonary embolism, has increased in cancer patients and adversely affects their prognosis. Low-molecular-weight heparins are recommended as efficacious and safe anticoagulation treatment in cancer patients. However, in practice, oral anticoagulation is preferred, especially if longterm or extended treatment is necessary. Novel oral anticoagulants have recently emerged as an alternative to the standard therapy owing to the ease of administration, predictable anticoagulation effect without the need of laboratory monitoring, and fewer drug interactions. These new agents have been shown as effective and safe for the management of cancer-associated thrombosis in ongoing head-to-head comparative trials. Here we review the advances and limitation of current anticoagulant therapies.

암환자의 치료범위를 벗어난 INR 원인 분석 (Causes for Non-therapeutic INRs in Cancer Patients: Single Center Analysis)

  • 박은;이혜숙;김향숙;아영미;이병구;이주연
    • 한국임상약학회지
    • /
    • 제23권3호
    • /
    • pp.232-238
    • /
    • 2013
  • Background: Although thromboembolism is common and one of the major causes of mortality in cancer patients, maintaining therapeutic anticoagulation effect with warfarin is challenging. This study aimed to determine the prevalence and the causes of non-therapeutic INR (International Normalized Ratio) in cancer patients. Methods: Medical and pharmacy records for cancer patients managed by the pharmacist-run anticoagulation service (ACS) between May, 2010 and April, 2011 at Seoul National University Hospital were retrospectively reviewed. The causes of non-therapeutic INR were identified and compared with the results from a former study with mechanical heart valve patients. Results: A total of 335 cancer patients and 6,737 patient-visits were analyzed producing 68% (n=4,590) of non-therapeutic INR readings. Eighty-five percent of the non-therapeutic INR readings were categorized as sub-therapeutic. Frequent causes linked to non-therapeutic INR included inadequate dosage adjustment (21.8%), changes in health status (11.8%), dietary changes (8.1%), and drug interactions (4.2%). More than half of the non-therapeutic INR values had no known etiology. As causes for non-therapeutic INR, changes in health status (p<0.0001), adverse reactions (p<0.0001), and dietary changes (p=0.017) were statistically more frequent in cancer patients than in patients with mechanical heart valves. Furthermore, exposure to sub-therapeutic INR were more prevalent in cancer patients than in patients with mechanical heart valve (p<0.0001). Conclusions: This study shows that there is a tendency to keep the level of INR low and that health status change, dietary change, and drug interactions are found to be frequent causes for non-therapeutic INR in cancer patients.

비타민 K길항제가 아닌 항응고제를 복용하는 환자들을 위한 치과 치료 (Dental Treatment for Patients with Non-Vitamin K Antagonist Oral Anticoagulant)

  • 성일용
    • 대한치과의사협회지
    • /
    • 제57권10호
    • /
    • pp.613-622
    • /
    • 2019
  • The vitamin K antagonist (VKA), cumadin, or warfarin, is the only antithrombotic drug that can be orally administered and has excellent effective for decades. However, it is cumbersome to periodically inspect the prothrombin time (PT) order to maintain adequate concentrations that do not cause bleeding, takes a few days to indicate therapeutic effects, gets affected by several factors such as food and drugs etc, and narrow in the therapeutic range. Although recently in development, the non-vitamin K antagonist anticoagulants(NOACs) exhibit a rapid onset of action and have relatively short half- lives compared to Coumadin. Because of these pharmacokinetic properties, it is possible to modify an individual's anticoagulation status quite rapidly, minimizing the period where the anticoagulation activity is therapeutically suboptimal. And the short half -lives of these drug allow for the relatively rapid reduction of their anticoagulation effects. There are currently no published clinical trials specifically assessing the bleeding risks associated with dental procedures for patients taking the NOACs. It is not necessary to interrupt NOAC medication for dental procedures that are likely to cause bleeding, but which have a low risk of bleeding complications. Because the bleeding risk for these procedures is considered to be low, the balance of effects is in favour of continuing the NOAC treatment without modification, to avoid increasing the risk of a thromboembolic event. The patients should be advised to miss(apixaban or dabigatran) or delay(rivaroxaban) a dose of their NOAC prior to dental procedures that are likely to cause bleeding and which have a higher risk of bleeding complications. Because the risk of bleeding complications for these procedures is considered to be higher, the balance effects is in favour of missing or delaying the pretreatment NOAC dose. The interruption is only for a short time to minimize the effect on thromboembolic risk.

  • PDF

심방세동 환자의 고주파 도자절제술 전.후의 항응고약물요법 사용실태 분석 (Evaluation of Peri-procedural Anticoagulation Drug Therapy undergoing Radiofrequency Ablation in Patients with Atrial Fibrillation)

  • 김수현;안성심;김순주;방준석;나현오
    • 한국임상약학회지
    • /
    • 제20권2호
    • /
    • pp.159-164
    • /
    • 2010
  • Radiofrequency ablation (RA) is being used to manage atrial fibrillation (AF) with patients failed at the $1^{st}$-line anti-arrhythmic medications. Patients undergoing this procedure are at increased risk of thromboembolism after ablation, and anticoagulation management surrounding the ablation remains controversial. Although no conclusive recommendations can be made, published guidelines and data support therapeutic anticoagulation with warfarin. The purpose of this study was to analyze effectiveness of current therapy and to find factors fluctuate International Normalized Ratio (INR) values in patients undergone RA followed by anticoagulation service (ACS). Retrospective review was conducted utilizing database in a hospital. Among 110 patients under warfarin around ablation between January 2006 to September 2007, 54 patients were selected and allocated into 2 groups: Group A included 47 who discontinued warfarin after ablation, while 7 in B continued the medication. Information on demographics, amount and length of warfarin dosing, INR values and measuring frequencies, and the causing factors on INR fluctuation were abstracted. Differences were analyzed using chi-squared test, Fisher's Exact test, and unpaired Student t-test. Mean amount of warfarin before and after surgery was 4.0 mg, 4.1 mg in Group A and was 5.1 mg, 4.6 mg in Group B, respectively. Average duration of warfarin doing before ablation was 73.7 days in Group A, 129.9 days in B with no significant difference (p = 0.312). The duration time of warfarin on groups after ablation lasted several months. The number of checking INRs was 4.1 and 7.6, respectively. Inter-individual variability of INR fluctuations were $2.1{\pm}0.6$ in Group A and $2.2{\pm}0.7$ in B which were not significantly different (p = 0.062). 164 cases of decreased INR were: 'omission in taking medication, stressfulness and headache, 'increased intake of high vitamin K foods', 'lifestyle change of increased physical activities', and 'increase of food-intakes'. To the contrary, 36 cases of increased INR were: 'reduce of food-intake', 'use of non-prescription drugs', 'reduction in physical activities', and 'excessive restriction on food-intake', consecutively. In conclusion, the study validated therapeutic outcomes of RA patients who we treated with standard guideline and demonstrated 9 factors of INR fluctuations in the patient. A well-trained, pharmacist-monitored anticoagulation service could reduce the risk of adverse effects and prevent complications in patients with AF around RA operation.

와파린-리팜핀 병용 시 용량 조절 (Dosage Adjustment before and after Warfarin - Rifampin Combination Therapy)

  • 김동현;김경환;최경희;이광자;이혜숙;손인자;김기봉;이재웅;안혁
    • Journal of Chest Surgery
    • /
    • 제41권3호
    • /
    • pp.354-359
    • /
    • 2008
  • 배경: 와파린은 항응고제로 쓰이는 약물로서 주로 간 대사에 의해 배설되는 약물이다. 리팜핀은 결핵 혹은 심내막염 등에 쓰이는 항생제로 2C9과 3A4를 포함한 CYP계열 효소 유도를 일으키는 대표적인 약물이다. 따라서 두 약물을 병용할 경우 리팜핀의 효소 유도에 의한 와파린 대사율 증가로 와파린의 항응고 효과는 감소한다. 이에 따라 와파린의 적절한 용량 조절이 요구되나 정확한 증량과 감량 정도는 제시되지 못하고 있는 실정이다. 이에 본 연구에서는 와파린 복용 환자 중 리팜핀을 병용하게 된 환자를 대상으로 두 약물의 병용 전후, 상호작용의 정도를 시간 경과에 따라 평가하고, 상호작용에 영향을 미치는 요인을 분석하고 또한 이를 토대로 두 약물의 병용 전후, 임상에서 활용할 수 있는 와파린 용량 결정 방법을 설정하고자 하였다. 대상 및 방법: OO병원 항응고 치료 상담 팀의 상담기록지를 1998년 1월부터 2006년 9월까지 후향적으로 검토하여 리팜핀을 병용하게 된 환자를 대상으로 하였다(n=15). 결과: 리팜핀 병용 전 전체 환자의 평균 INR은 $2.25{\pm}0.52$이며 병용 초기 100일간의 평균 INR은 $1.98{\pm}0.28$이었다. 이 경우 병용 전과 병용 초기의 평균 INR은 유의한 차이가 없었다(paired t-test, p>0.05). 리팜핀 병용 중단 직전 2회 측정한 INR의 평균은 $2.19{\pm}0.34$이고 병용 중단 이후 INR의 평균은 $2.49{\pm}0.43$으로 병용 중단 전과 후의 INR 평균은 유의한 차이를 보였으나(paired t-test, p<0.05)모두 치료유효역 범위 내에 있었다. 결론: 항응고 치료 상담 팀의 용량 조절이 적절하다고 판단하여 항응고 치료 상담 팀의 조절을 근거로 병용 시작 시와 병용 중단시의 와파린 용량조절 수식을 도출해냈다

와파린 복용 환자를 위한 메신저 기반 챗봇 개발 (Development of Warfarin Talk: A Messenger Chatbot for Patients Taking Warfarin)

  • 이한솔;김유리;신은정;장홍원;조윤희;조윤숙;김정훈;이주연
    • 한국임상약학회지
    • /
    • 제30권4호
    • /
    • pp.243-249
    • /
    • 2020
  • Background: Despite the increased use of direct-acting oral anticoagulants, warfarin is still recommended as first-line therapy in patients with mechanical valves or moderate to severe mitral stenosis. Anticoagulation management services (AMSs) are warranted for patients receiving warfarin therapy due to the complexity of warfarin dosing and large interpatient variability. To overcome limited health care resources, we developed a messenger app-based chatbot that provides information to patients taking warfarin. Methods: We developed "WafarinTalk" as an add-on to the open-source messenger app KakaoTalk. We developed the prototype chatbot after building a database containing seven categories: 1) dosage and indications, 2) drug-drug interactions, 3) drug-food interactions, 4) drug-diet supplement interactions, 5) monitoring, 6) adverse events, and 7) precautions. We then surveyed 30 pharmacists and 10 patients on chatbot reliability and on participant satisfaction. Results: We found that 80% of the pharmacists agreed on the consistency of chatbot responses and 44% agreed on the appropriateness of chatbot. Furthermore, 47% of pharmacists said that they were willing to recommend the chatbot to patients. Of the seven categories, information on drug-food interaction was the most useful; 90% of patients said they were satisfied with the chatbot and 100% of patients said they were willing to use it when they were unable to see a pharmacist. We updated the prototype chatbot with feedback from the survey. Conclusion: This study showed that warfarin-related information could be provided to patients through a messenger application-based chatbot.

Pharmacodynamic and pharmacokinetic interactions between herbs andwestern drugs

  • Lee, Ju-Young
    • Advances in Traditional Medicine
    • /
    • 제8권3호
    • /
    • pp.207-214
    • /
    • 2008
  • In recent years, the combined use of Herbal medicines and Western drugs has been increasing. Though certain problems may occur when both types of medicines are taken together, they havenot been adequately analyzed. It was reported that anticoagulation was enhanced in addition tobleeding when patients took long-term warfarin therapy in combination with Salvia miltiorrhiza(danshen), and laxative herbs accelerate intestinal transit and interfere with the absorption. Herbal constituents, curcumin, ginsenosides, piperine, catechins and silymarin were found to beinhibitors of P-glycoprotein. St John's wort induces the intestinal expression of P-glycoprotein. Anthraquinone, quercetin and coumarins were found to be a potent inhibitor of P-450. Glycyrrhizin or liquorice extracts, Garlic and St John's wort are a potent inducer of CYP3A4. This review provides a critical overview of interactions between herbal medicines and other drugs. Hence, it is necessary to study the pharmacodynamic and pharmacokinetic interactions of many herbal medicines between western drugs.

New Anticoagulants for the Prevention and Treatment of Venous Thromboembolism

  • Kim, Joo Hee;Lim, Kyung-Min;Gwak, Hye Sun
    • Biomolecules & Therapeutics
    • /
    • 제25권5호
    • /
    • pp.461-470
    • /
    • 2017
  • Anticoagulant drugs, like vitamin K antagonists and heparin, have been the mainstay for the treatment and prevention of venous thromboembolic disease for many years. Although effective if appropriately used, traditional anticoagulants have several limitations such as unpredictable pharmacologic and pharmacokinetic responses and various adverse effects including serious bleeding complications. New oral anticoagulants have recently emerged as an alternative because of their rapid onset/offset of action, predictable linear dose-response relationships and fewer drug interactions. However, they are still associated with problems such as bleeding, lack of reversal agents and standard laboratory monitoring. In an attempt to overcome these drawbacks, key steps of the hemostatic pathway are investigated as targets for anticoagulation. Here we reviewed the traditional and new anticoagulants with respect to their targets in the coagulation cascade, along with their therapeutic advantages and disadvantages. In addition, investigational anticoagulant drugs currently in the development stages were introduced.